Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric derisomaltose for cognitive function in chronic heart failure with iron deficiency
2021-005383-22Phase 4Active
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Mar 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA) and chronic heart failure (CHF), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Change in global composite cognitive function score at week 12. Started Mar 2022; status: active.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2021-005383-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005383-22.